| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 88.73▲ | 88.73▲ | 88.64▲ | 89.42▼ | 92.59▼ |
| MA10 | 89.75▼ | 89.75▼ | 89.98▼ | 89.30▼ | 90.13▼ |
| MA20 | 90.14▼ | 90.19▼ | 90.45▼ | 92.30▼ | 87.88▲ |
| MA50 | 93.12▼ | 93.38▼ | 93.58▼ | 89.69▼ | 78.31▲ |
| MA100 | 92.48▼ | 90.67▼ | 89.78▼ | 87.84▲ | 69.87▲ |
| MA200 | 89.79▼ | 88.27▲ | 87.27▲ | 81.34▲ | 58.67▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.017▲ | -0.017▼ | -0.101▼ | -0.712▼ | -0.175▼ |
| RSI | 42.303▼ | 42.178▼ | 42.472▼ | 46.163▼ | 56.304▲ |
| STOCH | 33.230 | 33.230 | 42.856 | 45.966 | 73.412 |
| WILL %R | -55.257 | -55.257 | -55.257 | -66.557 | -42.380 |
| CCI | -22.196 | -22.196 | -25.680 | -64.574 | 23.687 |
|
Monday, February 09, 2026 04:16 AM
Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment ...
|
|
Thursday, February 05, 2026 04:12 AM
Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver FailureRamat Gan, Israel, Feb. 05, 2026 ...
|
|
Wednesday, January 28, 2026 08:00 AM
Detailed price information for Can-Fite Biopharma Ltd ADR (CANF-A) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/02/26 | 87.71 | 89.63 | 87.25 | 89.10 | 12,800 |
| 12/02/26 | 89.25 | 89.3406 | 86.61 | 87.23 | 19,729 |
| 11/02/26 | 91.86 | 91.86 | 87.92 | 88.67 | 13,800 |
| 10/02/26 | 91.32 | 91.68 | 90.72 | 90.72 | 8,500 |
| 09/02/26 | 89.12 | 91.705 | 89.12 | 91.395 | 9,600 |
| 06/02/26 | 87.12 | 89.241 | 87.00 | 89.241 | 7,900 |
| 05/02/26 | 86.88 | 87.86 | 85.02 | 85.118 | 15,400 |
| 04/02/26 | 91.56 | 91.56 | 87.10 | 88.32 | 10,400 |
| 03/02/26 | 91.95 | 91.95 | 89.60 | 91.674 | 5,300 |
| 02/02/26 | 91.91 | 92.35 | 91.485 | 91.57 | 10,222 |
|
|
||||
|
|
||||
|
|